zagociguat 15 mg

DRUG2 trials

Sponsors

Tisento Therapeutics Inc.

Conditions

Mitochondrial encephalomyopathyand stroke-like episodes (MELAS)lactic acidosis

Phase 2

Phase 2b randomized, double-blind, placebo-controlled crossover study evaluating the efficacy and safety of zagociguat in participants with MELAS (PRIZM)

Active, not recruitingCTIS2024-515389-15-00

Tisento Therapeutics Inc.and stroke-like episodes (MELAS), lactic acidosis, Mitochondrial encephalomyopathy

Start: 2024-12-13Target: 20Updated: 2025-10-24

An open-label extension study evaluating the safety of zagociguat in participants with MELAS who completed TIS6463-203

Not yet recruitingCTIS2024-517514-15-00

Tisento Therapeutics Inc.and stroke-like episodes (MELAS), lactic acidosis, Mitochondrial encephalomyopathy

Target: 14Updated: 2025-07-25